Skip to main content
Clinical Trials/NCT06060691
NCT06060691
Completed
Phase 1

Randomized Controlled Trial Studying the Ameliorating Effects of Kaempferol Emulgel on Female Arousal Disorder and Sexual Dysfunction

Deraya University1 site in 1 country30 target enrollmentSeptember 20, 2023

Overview

Phase
Phase 1
Intervention
Kaempferol
Conditions
Female Sexual Dysfunction
Sponsor
Deraya University
Enrollment
30
Locations
1
Primary Endpoint
Female Sexual Function Index
Status
Completed
Last Updated
last year

Overview

Brief Summary

The aim of this study is to evaluate the quality of sexual life of females with sexual interest or arousal disorder before and after accurate application of a formulated emulgel made from natural ingredients, including kaempferol as an API

Registry
clinicaltrials.gov
Start Date
September 20, 2023
End Date
February 1, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women between the ages of 28 and 45
  • had regular periods and previous menstrual bleeding lasted between three and seven days

Exclusion Criteria

  • sensitivity to drug of therapy,
  • autoimmune illness,
  • smoking or drinking,
  • liver disease,
  • irregular menstruation

Arms & Interventions

Kaempferol group

Kaempferol gel received the vaginal gel containing antioxidant extract every day for seven days. Then, the treatment continued for two months, twice weekly

Intervention: Kaempferol

Placebo group

Plain formulation received the vaginal gel containing antioxidant extract every day for seven days. Then, the treatment continued for two months, twice weekly

Intervention: Kaempferol

Outcomes

Primary Outcomes

Female Sexual Function Index

Time Frame: two months

The FSFI comprises 19 questions of sexual function in six independent areas consisting of desire, arousal, lubrication, orgasm, sexual satisfaction , pain from sex.

Study Sites (1)

Loading locations...

Similar Trials